This study is in progress, not accepting new patients
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Summary
- Eligibility
- for people ages 65-85 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Adam Boxer
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Adam Boxer
Adam L. Boxer, MD, PhD is Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- ID
- NCT02008357
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 1150 study participants
- Last Updated